Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
Zin Z Htike, Francesco Zaccardi, Dimitris Papamargaritis, David R Webb, Kamlesh Khunti, Melanie J Davies
DIABETES OBESITY & METABOLISM | WILEY | Published : 2017
AIMS: To compare efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in people with type 2 diabetes. MATERIALS AND METHODS: We electronically searched, up to June 3, 2016, published randomized clinical trials lasting between 24 and 32 weeks that compared a GLP-1RA (albiglutide, dulaglutide, twice-daily exenatide and once-weekly exenatide, liraglutide, lixisenatide, semaglutide and taspoglutide) with placebo or another GLP-1RA. Data on cardiometabolic and safety outcomes were analysed using a mixed-treatment comparison meta-analysis. RESULTS: A total of 34 trials (14 464 participants) met the inclusion criteria; no published data for semaglutide were available. Compare..View full abstract
Awarded by National Institute for Health Research
F. Z. is a Clinical Research Fellow funded with an Educational Grant from Sanofi-Aventis to the University of Leicester. The research was supported by the National Institute for Health Research (NIHR) Diet, Lifestyle and Physical Activity Biomedical Research Unit, based at University Hospitals of Leicester and Loughborough University; and the NIHR CLARHC East Midlands. The views expressed are those of the authors and not necessarily those of the Sanofi-Aventis, NHS, the NIHR or the Department of Health.